compounded semaglutide crackdown news november 2025 FDA ESCALATES: 30 telehealth companies hit with warning letters for false claims on GLP-1 drugs. The agency accuses firms of misleading consumers by implying unapproved compounded versions match FDA-approved medications US judge upholds FDA's removal

According to FDA-approved labeling and clinical trial data, the following side effects occur most commonly: Gastrointestinal Effects: Nausea (affecting 1544% of patients, with higher rates at Wegovy doses) [3] [4] Diarrhea (reported in 830% of patients) Vomiting (524% incidence) Constipation (occurring in 324% of patients) Abdominal pain (520% of patients) These gastrointestinal symptoms typically emerge during dose escalation and often diminish with continued therapy as physiological adaptation occurs

GLPro GLPatch is not a GLP-1 drug - it's a botanical wellness patch the brand classifies as a dietary supplement

Similar results were seen in diabetic rats fed a diet rich in monounsaturated fatty acids from olive oil, where GLP-1 levels increased, weight gain decreased, and insulin sensitivity improved

If you encounter mild or occasional discomfort, it may subside as your body adapts to the medication

The repeated slashing of price by innovators is inability to justify the price premium but embrace this inevitable juggernaut